Can palbociclib control metastasis?

Palbociclib (Palbociclib) is a targeted therapy drug used to treat breast cancer. It is a CDK 4/6 inhibitor that prevents the proliferation of cancer cells by inhibiting the activity of cell cycle regulatory proteins CDK 4 and CDK 6. Due to its specific mechanism of action, palbociclib has shown certain efficacy in controlling breast cancer metastasis.

According to the results of clinical trials, palbociclib combined with endocrine therapy has shown significant survival benefits and tumor shrinkage in the treatment of breast cancer patients. It is approved for first- and second-line treatment of breast cancer. Palbociclib alone cannot completely control breast cancer metastasis and is often used in combination with drugs, such as anastrozole (Arimidex), exemestane (Aromasin), letrozole (letrozole) or fulvestrant (fulvestrant), to improve the efficacy. Clinical trials and guidelines generally recommend the use of palbociclib in the treatment of advanced or metastatic breast cancer, but exactly how long it should be used will vary based on individual circumstances.

The original drug of palbociclib has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be more than more than 4,000 yuan. The price of palbociclib's original drug, 125mg*21 capsules, per box sold overseas may be more than RMB 10,000 (the price may fluctuate due to exchange rates). There are also generic palbociclib drugs produced in other countries. The price of 125mg*21 tablets produced by a Bangladeshi pharmaceutical factory may be around a few hundred yuan per box (the price may fluctuate due to the exchange rate). The price is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.